Changes in U.S. model cast further doubt on EQRx’s goal of ‘radically’ lower pricing

EQRx management is insisting that its plan to price drugs drastically lower than competitors isn’t dead, although the company revealed Thursday that its two highest-priority programs will be priced in the U.S. via a “market-based” strategy.

On a conference call Thursday, CEO Melanie Nallicheri said EQRx Inc. (NASDAQ:EQRX) based its decision in part on FDA’s demands around two China-sourced drugs in its pipeline. The company is forecasting that its reprioritization decisions will create a “revenue gap” in the coming years...